Lenvatinib plus hepatic arterial infusion chemotherapy of oxaliplatin, fluorouracil, and leucovorin versus lenvatinib alone for advanced hepatocellular carcinoma: a multicenter retrospective cohort st
3 hours ago
- #Lenvatinib
- #HAIC
- #Hepatocellular Carcinoma
- Lenvatinib plus FOLFOX-HAIC significantly improved median PFS and OS compared to lenvatinib alone in advanced HCC patients (PFS: 12.3 vs. 6.2 months; OS: 25.6 vs. 12.3 months).
- Multivariate analysis identified lenvaHAIC treatment as an independent factor for improved PFS (HR 0.45) and OS (HR 0.38).
- Grade 3-4 adverse events, such as nausea and neutropenia, were more common in the lenvaHAIC group, but the safety profile was manageable.
- This real-world retrospective cohort study involved 127 patients in the combination group and 184 in the monotherapy group after matching from six Chinese centers.